Mr. Jayaraman to lead the company’s global sales and marketing
efforts as Cerus expands the U.S. launch of INTERCEPT platelets and
plasma and prepares for INTERCEPT red cell launch in Europe
CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today the appointment of Vivek
Jayaraman as chief commercial officer, effective August 29th, 2016. Mr.
Jayaraman joins Cerus from TriVascular Technologies, Inc. where he
previously served as vice president of sales and marketing.
“I am pleased to add Vivek to the Cerus team,” said William ‘Obi’
Greenman, president and chief executive officer of Cerus. “With our
progress to date with U.S. blood centers, including the American Red
Cross, and preparation for our European launch of the INTERCEPT red cell
system, it is now time to strengthen our global commercial leadership.
Vivek has an impressive track record of success in both large and small
organizations and possesses firsthand knowledge of what it takes to
scale commercially. We look forward to the many contributions Vivek will
bring to our mission of making INTERCEPT the global standard of care in
transfusion medicine.”
Mr. Jayaraman led TriVascular’s commercial expansion as the company grew
from a pre-clinical, venture-backed startup into a publicly traded,
global medical device company. At the time of its merger with Endologix,
Inc. (NASDAQ: ELGX) in February 2016, TriVascular’s products were sold
in over 30 countries. Prior to TriVascular, Mr. Jayaraman served in
roles of increasing responsibility at Medtronic, Inc.; most recently
serving as vice president of global marketing for Medtronic’s
endovascular innovations business. Mr. Jayaraman received his MBA from
the Wharton School at the University of Pennsylvania and holds dual
bachelor’s degrees from the University of Michigan.
“This is a great time to join Cerus, and I look forward to furthering
the commercial success of INTERCEPT platelets and plasma, and preparing
for the planned launch of INTERCEPT red cells,” said Mr. Jayaraman. “In
light of events across the globe and concerns about blood safety, the
corresponding need for INTERCEPT has never been greater. I am excited to
work with the team to ensure that blood centers, hospitals, physicians
and patients have access to INTERCEPT-treated blood components.”
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See www.cerus.com
for more information about Cerus.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.
Except for the historical statements contained herein, this press
release contains forward-looking statements concerning Cerus’
expectations regarding Cerus’ products, prospects and expected results,
including statements concerning Mr. Jayaraman success as Cerus’ new
chief commercial officer, the commercial success of the INTERCEPT Blood
System and potential approval and future launch of the red blood cell
system. Actual results could differ materially from these
forward-looking statements as a result of certain factors, including,
without limitation: risks associated with Cerus’ ability to effectively
integrate Mr. Jayaraman into its commercial team; the commercialization
and market acceptance of, and customer demand for, the INTERCEPT Blood
System; that Cerus may be unable to file for CE Mark approval of the red
blood cell system in Europe in the anticipated timeframe or at all, and
even if filed, Cerus may be unable to obtain CE Mark approval, or any
other regulatory approvals, of the red blood cell system in a timely
manner or at all, as well as other risks detailed in Cerus’ filings with
the Securities and Exchange Commission, including in Cerus‘ Quarterly
Report on Form 10-Q for the quarter ended June 30, 2016, filed with the
SEC on August 5, 2016. Cerus disclaims any obligation or undertaking to
update or revise any forward-looking statements contained in this press
release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160809005576/en/
Source: Cerus Corporation